🧬 Myositis-Specific Autoantibodies (MSAs) – 2025 Update MSAs aren’t just diagnostic—they predict phenotype, prognosis, & treatment response. 👇 Infographic #RheumTwitter #Myositis #MedEd @IhabFathiSulima @DrAkhilX https://t.co/91U5s88AdB

• https://x.com/Rheumat_Aravind/status/1946184560531923362/photo/1

Short full read review of the history, safety and use of Corticosteroids in Respiratory Medicine (including use in community-acquired pneumonia (CAP), ARDS, septic shock, ILD, COPD/asthma, COVID-19, Cancer, Sarcoid & IPF. https://t.co/aKMAT8IhLm https://t.co/RopoNnYJ6Z

• Frontiers | EDITORIAL: Safety of Corticosteroids in Respiratory Medicine

SSB, > SSA, Abs are signif associated w/ abnormal DLCO (AUC 0.791) in Sjogrens syndrome, esp in assoc. w/ LIP- lymphocytic interstitial pneumonitis. These findings more likely in quadruple positive Sjogrens w/ RF/ANA/SSA/SSB positivity. https://t.co/s6IyRzfXiN https://t.co/rKDBovTOpl

• The Role of Anti-SSB/La Antibodies as Predictors of Decreased Diffusing Capacit…

Sulfasalazine as a preventative against Pneumocystis (PJP). 594 RA pts & 848 Rx episodes - 181 on SSZ, 667 controls. W/ 850 Pt-Yrs F/U, 21developed PCP, 3 died of PCP. SSZ significantly lowered PJP risk (p = 0.003, rate ratio = 0.05; 95% CI 0.00–0.34). https://t.co/PAgBaJGldR https://t.co/PuTxGXTeRS

• Sulfasalazine as a Prophylactic for Pneumocystis Pneumonia in Patients With Rhe…

Study of a Chinese systemic JIA cohort using scRNA-seq and Bulk RNA-seq, found a potential biomarker w. UBE2D1 expression closely related to Dz activity levels, reflecting enhanced monocyte activity in sJIA patients. UBE2D1 may complement others S100A8/A9, IL-18, ferritin https://t.co/hp7sFR6kLa

Biologic survival study of British Assoc. of Dermatologists Biologics Register (11/07-6/23) looked at 19,034 Rx courses (median F/U 2.3 yrs), of TNFi, IL-12/23i, IL-17i, & IL-23i. IL-23i (GUS & RIS) had best survival (~1.93yrs) for efficacy & safety (broadalumab the least) https://t.co/uhomYmiUZy

10-20% of IBD pts have IBD-assoc. spondyloarthritis, as either peripheral arthritis or axial Dz, subclinical gut inflammation w/ IL-23–IL-17–TNFα playing central roles. TNFi & JAKi Rx is effective, but IL-17i may exacerbate IBD (vedolizumab??) Review here>> https://t.co/EL0sL2M3YX

GALAXI-2 and GALAXI-3 published showing the efficacy of IL-23 inhibitor, Guselkumab in a 48 week study in adults with moderately to severely active Crohn's disease. https://t.co/pWolec25cX https://t.co/e2fdcMxEro

• Efficacy and safety of intravenous induction and subcutaneous maintenance thera…

Molecular profiling of RA synovium predicts biologic responses Machine learning analysis of pre-treatment synovial tissue biopsy from RA patients starting either ETN, TCZ and RTX revealed high accuracy prediction of 16 week outcomes unique to each biologic. https://t.co/4d6NEY6JN6

MTX lowers risk of serious infxn (SI) - UK Observational study of 17 472 newly Dx RA (2018–2023); 10K on MTX, 4,540 other csDMARDs; 13680 corticosteroids (GC). 1307 SI (3/100 PY) w/ reduced adj HR 0.72 (95% CI: 0.63–0.82). 311 SI-related mortality (IR 0.69;0.61–0.77) https://t.co/YhJV3vyAmB

1 in 5 Patients are Unaware of their Arthritis Diagnosis Current CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA. Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million). https://t.co/G8zeP1K5X9 https://t.co/BdDFVSUuFf

• 1 in 5 Patients are Unaware of their Arthritis Diagnosis | RheumNow

French Teratology Service study of 57 pregnant women exposed to anti-IL-1 (47% for Stills Dz) found no evidence of adverse pregnancy outcomes with IL-1 inhibition (43 anakinra, 5 canakinumab) 85% livebirths, 11% early miscarriages. Major congenital malformations 3% https://t.co/iyLvaNKA2o